SNMMI backs bill to change radiopharmaceutical policy


SNMMI and its coalition of patient advocacy partners support The Facilitating Innovative Nuclear Diagnostics Act of 2021, which would change the CMS policy of bundling diagnostic PET radiopharmaceuticals in hospital outpatient procedures. "Innovative radiopharmaceuticals are revolutionizing the diagnosis and treatment of a wide variety of diseases, but under current CMS payment policies, these remarkable agents often are not available to Medicare beneficiaries, resulting in inequities in health care," said SNMMI President Dr. Richard Wahl

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.